

PROVIDER Update



CONTRACTUAL | SEPTEMBER 25, 2025 | UPDATE 25-1017 | 6 PAGES

2nd Quarter 2025 Injectable Medication HCPCS/DOFR Crosswalk

Use the updates for dates of service on and after December 2, 2025

The Health Net* Pharmacy Advisory Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. The Pharmacy Advisory Committee members include physicians and pharmacists.

The approved updates, effective December 2, 2025 are listed on pages 2-6 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net* *Provider Participation Agreement (PPA)*.

The update includes:

- 16 new injectable medications to be added to the DOFR crosswalk
- 40 updates and changes to current injectable medication procedure codes
- 15 new biosimilars and updates to be added to the DOFR Crosswalk
- 3 updates for new generic drugs

Additional information

Relevant sections of Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on Health Net's provider portal at provider.healthnetcalifornia.com > *Provider Library* under Quick Links, or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center listed in the right hand column.

THIS UPDATE APPLIES TO:

- Participating Physician Groups

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer Group
 - HMO/POS
 - PPO
- Medi-Cal
 - Amador
 - Calaveras
 - Inyo
 - Los Angeles
 - Molina
 - Mono
 - Sacramento
 - San Joaquin
 - Stanislaus
 - Tulare
 - Tuolumne

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP

Ambetter HMO – 888-926-2164

Ambetter from Health Net IFP

Ambetter PPO – 844-463-8188

Health Net Employer Group

HMO, POS & PPO – 800-641-7761

Medi-Cal (including CS and ECM providers)
– 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

*Health Net of California, Inc. and Health Net Community Solutions, Inc. are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0172	Azmiro™	Injection, testosterone cypionate, 1 milligrams (mg)	Therapeutic injection	
J9999	Emrelis™	Telisotuzumab vedotin-tllv for injection, for intravenous (IV) use	Therapeutic injection	Chemotherapy ¹
J3590	Encelto™	Revakinagene taroretcel-lwey intravitreal implant 200,000 cells	Therapeutic injection	
A9611	Flyrcado™	Flurpiridaz F 18 IV solution 5-55 mCi/ milliliters (ml) (190-2,050 megabecquerels (MBq)/ml)	Diagnostic agent	Not included in DOFR crosswalk
J9999	Grafapex™	Treosulfan for injection for IV use	Therapeutic injection	Chemotherapy ¹
J3590	Imaavy™	Nipocalimab-Aahu IV solution	Therapeutic injection	
J9249	Ivra™	Melphalan HCl IV solution 90 mg/ml (base equivalent)	Therapeutic injection	Chemotherapy ¹
J0364	Onapgo™	Apomorphine hydrochloride (HCl) solution cartridge	Self-injectable	
J9999	Penpulimab-kcqx	Penpulimab-kcqx injection for IV use	Therapeutic injection	Chemotherapy ¹
J3490	Qfitlia™	Fitusiran injection for subcutaneous use	Therapeutic injection	Blood/blood products for hemophilia
J2547	Rapiblyk™	Landiolol HCl for IV solution 280 mg	Therapeutic injection	
J3590	Ryoncil®	Remestemcel-L-rknd 2 x 3.8 ml suspension for IV infusion kit	Therapeutic injection	
J9342	Tepadina®	Injection, thiotepa, not otherwise specified, 1 mg	Therapeutic injection	Chemotherapy ¹
J9341	Tepylute®	Thiotepa for IV solution	Therapeutic injection	Chemotherapy ¹
J9275	Unloxcyt™	Injection, cosibelimab-ipdl, 2 mg	Therapeutic injection	Chemotherapy ¹
90593	Vimkunya™	Chikungunya vaccine recombinant virus-like particle IM suspension pre-filled syringe 40 mcg/0.8ml	Therapeutic injection	Immunization

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

Updates/changes to injectable medication procedure codes or HCPCS codes

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J3303	Aristospan® intra-articular	Triamcinolone hexacetonl injection	Code deleted
Q2058	Aucatzyl®	Obecabtagene autoleucel suspension for intravenous infusion	Replaces J3590
J3355	Bravelle®	Urofollitropin, 75 international unit (IU)	Discontinued
90684	Capvaxive™	Pneumococcal 21-valent conjugate vaccine injection, for intramuscular use	Replaces J3590
J1020	Depo-medrol® 20	Methylprednisolone 20 mg injection	Code deleted
J1030	Depo-medrol® 40	Methylprednisolone 40 mg injection	Code deleted
J1040	Depo-medrol® 80	Methylprednisolone 80 mg injection	Code deleted
J1010	Depo-medrol®	Injection, methylprednisolone acetate, 1 mg	New code replaces J1020, J1030, J1040
J1100	Dexamethasone sodium phosphate	Dexamethasone sodium phosphate 1 mg	Code deleted
J1180	Dilor	Dyphylline injection	Discontinued
C9304	Hympavzi™	Marstacimab-hncq injection, for subcutaneous use	Replaces J3590
J3391	Lenmeldy™	Atidarsagene autotemcel IV suspension	Replaces J3590
J3490	Luveris®	Lutropin alfa for subcutaneous injection 75 unit	Discontinued
J2919	Solu-medrol®	Methylprednisolone sodium succinate for injection PF 500	Code deleted
J9289	Opdivo qvantig™	Nivolumab and hyaluronidase-nvhy injection, for subcutaneous use	Replaces J9999
J0725	Profasi®	Chorionic gonadotropin/1000 IU	Discontinued
J0725	Profasi HP®	Chorionic gonadotropin/1000 IU	Discontinued
J3590	Repronex®	Menotropins 75 IU	Discontinued

Updates/changes to injectable medication procedure codes or HCPCS codes, *continued*

HCPCS	Drug name	Generic name	Comment
Q9998	Selarsdi™	ustekinumab-aekn is biosimilar* to Stelara®	Replace J3590
J1720	Solu-cortef®	Hydrocortisone sodium succinate	Code deleted
Q5099	Steqeyma®	Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg	Replaces J3590
J1590	Tequin®	Gatifloxacin injection	Discontinued
J2725	Thyrel® TRH	Protirelin per 250 mcg	Discontinued
S0040	Ticarcillin	Ticarcillin disodium	Discontinued
J0365	Trasylol®	Aprotonin, 10,000 Kallikrein Inactivator Units (KIU)	Discontinued
J3301	Triamcinolone acetonide USP	Triamcinolone acetonide injection	Code deleted
J1642	Vasceze™	Heparin sodium injection per 10 USP	Discontinued
90393	Vaccinia	Vaccinia immune globulin (VIG), human, intramuscular (IM)	Discontinued
J0900	Valertest #1	Testosterone enanthate and estradiol valerate	Discontinued
J3372	Vancomycin	Injection, vancomycin hydrochloride	New code
J3400	Vesprin	Triflupromazine hydrochloride (HCl) injection	Discontinued
J9219	Viadur®	Leuprolide acetate implant	Discontinued
J7356	Vyalev™	Foslevodopa-foscarbidopa subcutaneous injection	Replaces J3490
Q5100	Yestintek™	Injection, ustekinumab-kfce (yesintek), biosimilar, 1mg	Replaces J3590
J0691	Xenleta™	Lefamulin injection, for intravenous use	Discontinued
J7513	Zenapax®	Daclizumab 25 mg, parenteral	Discontinued
90736	Zostavax™	Zoster (shingles) vaccine, live, for subcutaneous injection	Discontinued
J9276	Ziihera®	Zanidatamab-hrii injection IV solution	Replaces J9999
J2311	Zimhi™	Injection, naloxone HCl, 1 mg	Replaces J2310
C9303	Vyloy®	Zolbetuximab-clzb	Replaces J9999

New biosimilars to be added to the DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Bomynta®	Denosumab 120mg/1.7ml, injection, for subcutaneous use (biosimilar to Xgeva®)	Therapeutic injection	Chemotherapy adjunctive ¹
J3590	Conexence®	Denosumab-bnht injection, for subcutaneous use (biosimilar to Prolia®)	Therapeutic injection	
Q5098	Imuldosa™	Injection, ustekinumab-srlf, (biosimilar for Stelara), 1 mg	Self-injectable	
Q5136	Jubbonti®	Denosumab-bbdz injection solution prefilled syringe (biosimilar to Prolia)	Therapeutic injection	
J3590	Jobevne™	Bevacizumab-nwgd injection, (biosimilar to Avastin®)	Therapeutic injection	
Q5153	Opuviz™	Aflibercept-yszy injection, for intravitreal use (biosimilar to Eylea®)	Therapeutic injection	
Q9999	Otulfi™	Ustekinumab-aaaz solution prefilled syringe 45 mg/0.5ml (biosimilar to Stelara)	Self-injectable	
Q9999	Otulfi™	Ustekinumab-aaaz solution prefilled syringe 90 mg/ml (biosimilar to Stelara)	Self-injectable	
Q9999	Otulfi™	Injection, ustekinumab-aaaz, biosimilar to Stelara, 1 mg, IV	Therapeutic injection	
Q5142	Simlandi®	Adalimumab-ryvk injection (biosimilar to Humira®), 1 mg	Self-injectable	
Q9996	Pyzchiva®	Injection, ustekinumab-ttwe, subcutaneous, 1 mg biosimilar to Stelara	Self-injectable	
Q9997	Pyzchiva®	Injection, ustekinumab-ttwe, IV, 1 mg biosimilar to Stelara	Therapeutic injection	
Q9998	Selarsdi™	Injection, ustekinumab-aekn, 1 mg, biosimilar to Stelara	Self-injectable	

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

New biosimilars to be added to the DOFR crosswalk, *continued*

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Steqeyma®	Injection, ustekinumab-stba, biosimilar to Stelara, 1 mg	Self-injectable	
Q5150	Ahzantive®	Injection, aflibercept-mrbb, biosimilar to Eylea 1 mg	Therapeutic injection	

New generic injectable medications

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0616	Metoprolol	Injection, metoprolol tartrate, 1 mg	Therapeutic injection	
J1954	Leuprolide acetate for depot	Injection, leuprolide acetate for depot suspension (ciplā), 7.5 mg	Therapeutic injection	Chemotherapy adjunctive ¹
J1954	Leuprolide acetate for depot	Injection, leuprolide acetate for depot suspension (ciplā), 7.5 mg	Therapeutic injection	Chemotherapy adjunctive ¹

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.